Board of Directors at its meeting held today on 04.11.2025 interalia approved un-audited financial results(both standalone and consolidated) for the quarter/half year ended 30.09.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Sunil Healthcare Ltd approved unaudited financial results (standalone and consolidated) for the quarter and half year ended September 30, 2025. Standalone revenue from operations grew about 16% year-on-year in Q2 to Rs 2,351.76 lakhs (from Rs 2,025.77 lakhs) and H1 revenue rose to Rs 4,615.95 lakhs (from Rs 4,175.32 lakhs), about 10% growth. Standalone profit after tax improved meaningfully from a very small base of around Rs 3 lakhs in Q2 FY25 to about Rs 79 lakhs in Q2 FY26. On a consolidated basis, the company swung to a small profit of roughly Rs 19-20 lakhs in H1 FY26 from a loss of about Rs 124 lakhs in H1 FY25. Auditor Singhi & Co. issued an unqualified (clean) limited review report with no qualifications or emphasis of matter.
The results show steady top-line growth and a return to consolidated profitability, which is mildly positive. However, operating cash flow turned sharply negative on a consolidated basis (about Rs -282 lakhs in H1 FY26 vs Rs +444 lakhs in H1 FY25), suggesting working capital stress that investors should watch closely despite the headline profit improvement.